- Home
- KROS vs ORC Comparison
KROS vs ORC Comparison
Compare KROS & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ORC
- Stock Information
- Founded
- KROS 2015
- ORC 2010
- Country
- KROS United States
- ORC United States
- Employees
- KROS N/A
- ORC N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ORC Real Estate Investment Trusts
- Sector
- KROS Health Care
- ORC Real Estate
- Exchange
- KROS Nasdaq
- ORC Nasdaq
- Market Cap
- KROS 460.6M
- ORC 623.6M
- IPO Year
- KROS 2020
- ORC 2013
- Fundamental
- Price
- KROS $11.13
- ORC $8.28
- Analyst Decision
- KROS Buy
- ORC Buy
- Analyst Count
- KROS 11
- ORC 3
- Target Price
- KROS $45.33
- ORC $9.50
- AVG Volume (30 Days)
- KROS 2.1M
- ORC 3.0M
- Earning Date
- KROS 02-26-2025
- ORC 01-30-2025
- Dividend Yield
- KROS N/A
- ORC 17.43%
- EPS Growth
- KROS N/A
- ORC N/A
- EPS
- KROS N/A
- ORC 0.58
- Revenue
- KROS $651,000.00
- ORC $54,406,000.00
- Revenue This Year
- KROS $303.27
- ORC N/A
- Revenue Next Year
- KROS N/A
- ORC N/A
- P/E Ratio
- KROS N/A
- ORC $14.41
- Revenue Growth
- KROS 8037.50
- ORC N/A
- 52 Week Low
- KROS $9.78
- ORC $7.41
- 52 Week High
- KROS $73.00
- ORC $9.08
- Technical
- Relative Strength Index (RSI)
- KROS 25.01
- ORC 62.14
- Support Level
- KROS $11.04
- ORC $7.88
- Resistance Level
- KROS $11.36
- ORC $8.38
- Average True Range (ATR)
- KROS 0.53
- ORC 0.18
- MACD
- KROS 1.15
- ORC 0.04
- Stochastic Oscillator
- KROS 37.80
- ORC 81.51
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.